Kalydeco (Ivacaftor)

Ivacaftor binds to the CFTR protein and increases the likelihood that the chloride channel stays open. This potentiation restores chloride transport across epithelial cells, leading to better hydration of airway surfaces, thinner mucus, and improved respiratory function in individuals with specific CFTR mutations.

The dosage of Kalydeco is individualized by the prescribing clinician based on the patient’s age, weight, and specific CFTR mutation profile. The prescriber determines the appropriate tablet strength and dosing schedule, and patients should follow the exact regimen provided in their prescription.

Safety data for ivacaftor during pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should only be used when the potential benefits to the mother outweigh any possible risks to the fetus or infant, and the decision should be made in consultation with a healthcare professional.

To request Kalydeco, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Kalydeco (ivacaftor) is a CFTR potentiator used for gating mutations, whereas combination products such as lumacaftor/ivacaftor (Orkambi) or tezacaftor/ivacaftor (Symdeko) combine a corrector with a potentiator to treat the F508del mutation. Kalydeco is typically chosen when a patient has a gating mutation that responds directly to potentiation, offering a more targeted approach.

Kalydeco tablets should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original blister pack to protect them from moisture and light. Do not store in a refrigerator or freezer, and keep out of reach of children.

Kalydeco is taken orally as a tablet, usually with a glass of water. The tablets can be swallowed whole or, if necessary, crushed and mixed with soft food, provided the patient consumes the entire mixture promptly. Administration should follow the schedule prescribed by the treating physician.

Serious risks include elevations in liver enzymes (ALT/AST), which require regular monitoring, the possible development of cataracts, and severe skin reactions such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. Patients should report any signs of liver dysfunction, visual changes, or rash to their healthcare provider immediately.

Kalydeco should not be used by individuals with a known hypersensitivity to ivacaftor or any of the tablet excipients. It is also contraindicated in patients with severe liver impairment or those taking strong CYP3A4 inducers that would markedly reduce drug exposure. Clinical judgment is required for patients with other significant comorbidities.